Antibody Conjugate Therapeutics: Challenges and Potential

Antibody conjugates are a diverse class of therapeutics consisting of a cytotoxic agent linked covalently to an antibody or antibody fragment directed toward a specific cell surface target expressed by tumor cells. The notion that antibodies directed toward targets on the surface of malignant cells could be used for drug delivery is not new.

The history of antibody conjugates is marked by hurdles that have been identified and overcome. Early conjugates used mouse antibodies; cytotoxic agents that were immunogenic (proteins), too toxic, or not sufficiently potent; and linkers that were not sufficiently stable in circulation.

  • Antibody-Drug Conjugates Design And Development
  • Bispecific antibody conjugates in therapeutics
  • Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
  • New Developments in Antibody-Drug Conjugates

Related Conference of Antibody Conjugate Therapeutics: Challenges and Potential

Antibody Conjugate Therapeutics: Challenges and Potential Conference Speakers